ConductScience.org, home

Comparison · NCT03169972-sae

Previously Treated Patients (PTPs) vs Previously Untreated Patients (PUPs): serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Previously Treated Patients (PTPs) vs Previously Untreated Patients (PUPs): serious adverse events. Trial comparisons, record NCT03169972-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03169972-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01630.004470.0574wilson
Risk in group 20.08330.01490.354wilson
Risk difference, group 1 minus group 2-0.0671-0.3380.0128newcombe hybrid score
Risk ratio, group 1 over group 20.1950.01912log
Odds ratio, group 1 over group 20.1820.01522.17log
Number needed to treat, for one fewer participant with a serious adverse event on Previously Treated Patients (PTPs) than on Previously Untreated Patients (PUPs)14.9from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Previously Treated Patients (PTPs)
Participants with hemophilia A who received Recombinant Factor VIII (FVIII) PEGylated (ADYNOVATE) intravenous Infusion as part of a routine medical care. Participants in this group were previously treated patients with Factor VIII deficiency (PTPs) who had 4 or more exposure days to other Factor VIII (FVIII) products.
2123EG000
Group 2Previously Untreated Patients (PUPs)
Participants with hemophilia A who received Recombinant Factor VIII (FVIII) PEGylated (ADYNOVATE) intravenous Infusion as part of a routine medical care. Participants in this group were previously untreated patients with Factor VIII deficiency (PUPs) who had 3 or less previous exposure days to other Factor VIII (FVIII) products.
112EG001

Harm

What it counts
Total, serious adverse events
Time frame
Up to 1 year for previously treated patients (PTPs) or up to 2 years for previously untreated patients (PUPs)

Source ClinicalTrials.gov

Trial

Title
ADYNOVATE Drug Use-Results Survey
NCT number
NCT03169972
Phases
Conditions
Hemophilia A
Interventions
ADYNOVATE
Lead sponsor
Takeda
Results first posted
2025-02-04

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03169972-sae